Zebrafish Drug Screening Platform for Mitochondrial Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug screening methods for epilepsy and other brain dysfunction disorders are inefficient, as they primarily focus on plasma membrane-bound ion channels and enzymes, failing to effectively modulate mitochondrial function, which is crucial for treating conditions like epilepsy where 250,000 people in Canada do not respond to existing drugs.
Innovation Solution
A novel drug screening platform using genetically altered zebrafish models that correspond to human genes associated with brain dysfunction disorders, allowing for the identification of compounds that modulate mitochondrial function by assessing changes in mitochondrial outputs such as ATP levels and respiration rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug screening focuses on plasma membrane-bound ion channels and enzymes, then the screening process is well-established and can be performed using conventional methods, but the efficacy is limited and fails to effectively modulate mitochondrial function in brain dysfunction disorders
Solution Approach 1:
The patent segments the cellular target scope into two distinct categories: traditional plasma membrane-bound targets (ion channels, transporters, enzymes) and the newly added mitochondrial targets. This segmentation allows the screening platform to systematically evaluate both conventional and emerging therapeutic targets independently, thereby expanding the adaptability of drug screening while maintaining the reliability of established methodologies for plasma membrane targets.
Solution Approach 2:
The patent creates a universal drug screening platform that can simultaneously evaluate compounds against multiple target types (plasma membrane-bound targets and mitochondrial targets) using a single integrated system. The use of zebrafish models with humanized gene expression enables the platform to universally assess drug efficacy across different target classes and disease models, enhancing both the versatility and reliability of the screening process.
2Reliability
If zebrafish models with humanized genes are used for drug screening, then the relevance to human brain dysfunction disorders is improved, but the complexity of the screening platform increases
Solution Approach 1:
The patent employs copying by creating zebrafish models that carry humanized versions of disease-associated genes (such as KCNQ3, SCN1A, and GABRB3). Instead of directly studying human brain tissue, the system copies the relevant human genetic pathways into a simpler vertebrate model, thereby improving human disease relevance while maintaining the operational simplicity and scalability of zebrafish systems.
Solution Approach 2:
The zebrafish model serves as an intermediary system between human genetic disease mechanisms and drug screening assays. The humanized genes in zebrafish act as mediators that translate human disease pathology into a tractable model organism, allowing researchers to study human-specific disease mechanisms without the complexity of working directly with human tissue, thus balancing reliability with manageable system complexity.
3Adaptability or versatility
If mitochondrial function is assessed as a readout for drug screening, then the ability to identify compounds that modulate mitochondrial function is improved, but the measurement methodology becomes more complex compared to traditional ion channel assays
Solution Approach 1:
The patent utilizes colorimetric or fluorescent indicators that change color or emit light in response to mitochondrial function parameters such as ATP production, membrane potential, or oxygen consumption. These visual changes provide a simple, intuitive readout that can be detected using standard plate readers or imaging systems, thereby simplifying the measurement of mitochondrial outputs while maintaining the ability to detect and quantify mitochondrial activity in high-throughput formats.
Solution Approach 2:
The patent replaces complex mechanical or electrophysiological measurement systems with optical or biochemical assays to detect mitochondrial function. Instead of using sophisticated equipment to measure ion channel activity or mitochondrial membrane potential directly, the system uses optical sensors, fluorescent dyes, or metabolic substrates that convert mitochondrial activity into easily measurable signals, reducing the difficulty of detection while preserving the versatility of mitochondrial target assessment.
Data Source
AI summary
The present application provides a novel drug screening platform designed to identify drugs that favorably modulate cellular bioenergetics in the human brain of a zebrafish which has been modified by altering a teleost gene that corresponds to a human gene associated with a brain dysfunction disorder (such as epilepsy). The drug screening platform are also useful for determining a mutation in a human gene associated with a brain dysfunction disorder that is associated with a human individual responsive to the treatment of a compound. Also provided are modified teleosts useful for the methods described herein.